The Economic Impact of Mitral Regurgitation on Patients With Medically Managed Heart Failure

McCullough, Peter A.; Mehta, Hirsch; Barker, Colin M.; Cork, David P.; Gunnarsson, Candace; Ryan, Michael P.; Baker, Eileen F.; Houten, Joanna Van; Mollenkopf, Sarah; Verta, Patrick

doi:10.1016/j.amjcard.2019.07.033

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several studies have reported on the medical care costs of MR, evidence on the direct healthcare costs of MR and data on the comparisons between the different MR types remains limited [ 13 , 14 ]. Studies have focused on Western populations or business insurance populations and provided little evidence on the healthcare cost for MR in Asians.…”

Section: Introductionmentioning

confidence: 99%

One-Year Healthcare Utilization and Expenditures Among Patients with Clinically Significant Mitral Regurgitation in Taiwan

Chung

Wang²,

Lee³

2022

Cardiol Ther

View full text Add to dashboard Cite

Introduction: Mitral regurgitation (MR) is characterized by systolic blood flow reversal from the left ventricle to the left atrium. A 2019 study indicated that in the USA, clinically significant MR (sMR) is associated with a substantial healthcare cost burden. In Taiwan, few data are available to describe the clinical characteristics, treatment patterns, and economic burden of patients with sMR. Methods: Using the National Health Insurance Research Database (NHIRD), a national, detailed claims database of all 23 million residents of Taiwan, we conducted a retrospective cohort study to identify patients with sMR and quantify the impact of the disease on Taiwan's healthcare system. We classified patients with sMR into three cohorts based on disease etiology: functional MR (sFMR), degenerative MR (sDMR), and uncharacterized MR (sUMR).

show abstract

Section: Introductionmentioning

confidence: 99%